Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia.

Caselli, Désirée
CESARO, SIMONE
Aricò, Maurizio

January 2016

Advances in chemotherapy and surgery allows the majority of patients to survive cancer diseases. Yet...

Comparison of the effects of two different doses of Filgrastim in febrile neutropenia management in childhood malignancy: A randomized clinical trial

Mirbehbahani, N.
Bagheri, S.
Roshandel, G.
Jahazi, A.
Rashidbaghan, A.

January 2022

Background: Febrile neutropenia (FN) is most often caused due to chemotherapy. Solid or certain lymp...

ONE YEAR OF BIOSIMILAR FILGRASTIM IN ROUTINE CLINICAL PRACTICE

Maria Sofia Rosati
Giulia Baciarello
Maria Luisa Basile
Serena Zancla
Ersilia Ranieri

January 2012

Objectives: The use of biosimilar filgrastim has been debated for the limited experience at the time...

Sevinç A.
Özkan M.
Özet A.
Dane F.
Öksüzoğlu B.
Işikdoğan A.
Özdemir F.

January 2018

Background: We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim...

Sevinç A
Özkan M
Özet A
Dane F
Öksüzoğlu B
Işıkdoğan A
Özdemir F
Uncu D
Gümüş M
Evrensel T
Yaren A
Kara O
Tekin SB

January 2018

BACKGROUND: We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim...

Sevinc, Alper and Ozkan, Metin and Ozet, Ahmet and Dane, Faysal and Oksuzoglu, Berna and Isikdogan, Abdurrahman and Ozdemir, Feyyaz and Uncu, Dogan and Gumus, Mahmut and Evrensel, Turkkan and Yaren, Arzu and Kara, Oguz and Tekin, Salim Basol

January 2018

Background: We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim...

neutropenia

Sevinc, A
Ozkan, M
Ozet, A
Dane, F
Oksuzoglu, B
Isikdogan, A
Ozdemir, F
Uncu, D
Gumus, M
Evrensel, T
Yaren, A
Kara, O
Tekin, SB

January 2018

Background: We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim...

neutropenia

Sevinc, A
Ozkan, M
Ozet, A
Dane, F
Oksuzoglu, B
Isikdogan, A
Ozdemir, F
Uncu, D
Gumus, M
Evrensel, T
Yaren, A
Kara, O
Tekin, SB

January 2018

Background: We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim...

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar

Schwartzberg LS
Lal LS
Balu S
Campbell K
Brekke L
Elliott C
Korrer S

September 2018

Lee S Schwartzberg,1,2 Lincy S Lal,3 Sanjeev Balu,4 Kim Campbell,4 Lee Brekke,3 Caitlin Elliott,3 St...

A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients

Roberto Hegg
André Mattar
João Nunes de Matos-Neto
José Luiz Pedrini
Sabina Bandeira Aleixo
Roberto Odebrecht Rocha
Renato Peixoto Cramer-Junior
Sylvie van-Eyll-Rocha

OBJECTIVES: To compare the efficacy and safety of two filgrastim formulations for controlling chemot...

Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy

Kalpna Desai
Priya Misra
Sanyukta Kher
Nirmesh Shah

September 2018

Abstract Background Chemotherapy-induced neutropenia is a common result of myelosuppressive chemothe...

The Real-World Experience of the Biosimilar (Grastofil®) to the Reference Biologic (Neupogen®) in Breast Cancer and Lymphoma: A Canadian Single-Centre Retrospective Study

Wong, Gina
Wang, Katie
Pasetka, Mark
Zhang, Liying
Lou, Julia
Majeed, Habeeb
Flores, Jerome
Lam, Emily
DeAngelis, Carlo

February 2022

Febrile neutropenia (FN) is a common side effect of cytotoxic chemotherapy that may result in poor t...

Shahab, Shania
S, Ahmad

January 2024

7-15Biologics have no true generics due to their complex nature but biosimilars offer a hopeful alte...

Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study

Shi, Yuan-Kai
Chen, Qiang
Zhu, Yun-Zhong
He, Xiao-Hui
Wang, Hua-Qing
Jiang, Ze-Fei
Chang, Jian Hua
Liu, Yun-Peng
Wang, An-Lan
Luo, De-Yun
Zhang, Yang
Ke, Xiao-Yan
Li, Wei-Lian
Zhang, Wei-Jing
Wang, Xiu-Wen
Zhang, Yi-Ping
Wang, Jian-Min
Liu, Xiao-Qing

January 2013

The purpose of this study was to compare the efficacy and safety of a single subcutaneous injection ...

A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients

Hegg, Roberto
Mattar, André
Matos-Neto, João Nunes de
Pedrini, José Luiz
Aleixo, Sabina Bandeira
Rocha, Roberto Odebrecht
Cramer-Junior, Renato Peixoto
van-Eyll-Rocha, Sylvie

October 2016

OBJECTIVES: To compare the efficacy and safety of two filgrastim formulations for controlling chemot...

Caselli, Désirée
CESARO, SIMONE
Aricò, Maurizio

January 2016

Advances in chemotherapy and surgery allows the majority of patients to survive cancer diseases. Yet...

Comparison of the effects of two different doses of Filgrastim in febrile neutropenia management in childhood malignancy: A randomized clinical trial

Mirbehbahani, N.
Bagheri, S.
Roshandel, G.
Jahazi, A.
Rashidbaghan, A.

January 2022

Background: Febrile neutropenia (FN) is most often caused due to chemotherapy. Solid or certain lymp...

ONE YEAR OF BIOSIMILAR FILGRASTIM IN ROUTINE CLINICAL PRACTICE

Maria Sofia Rosati
Giulia Baciarello
Maria Luisa Basile
Serena Zancla
Ersilia Ranieri

January 2012

Objectives: The use of biosimilar filgrastim has been debated for the limited experience at the time...

Sevinç A.
Özkan M.
Özet A.
Dane F.
Öksüzoğlu B.
Işikdoğan A.
Özdemir F.

January 2018

Background: We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim...

Sevinç A
Özkan M
Özet A
Dane F
Öksüzoğlu B
Işıkdoğan A
Özdemir F
Uncu D
Gümüş M
Evrensel T
Yaren A
Kara O
Tekin SB

January 2018

BACKGROUND: We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim...

Sevinc, Alper and Ozkan, Metin and Ozet, Ahmet and Dane, Faysal and Oksuzoglu, Berna and Isikdogan, Abdurrahman and Ozdemir, Feyyaz and Uncu, Dogan and Gumus, Mahmut and Evrensel, Turkkan and Yaren, Arzu and Kara, Oguz and Tekin, Salim Basol

January 2018

Background: We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim...

neutropenia

Sevinc, A
Ozkan, M
Ozet, A
Dane, F
Oksuzoglu, B
Isikdogan, A
Ozdemir, F
Uncu, D
Gumus, M
Evrensel, T
Yaren, A
Kara, O
Tekin, SB

January 2018

Background: We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim...

neutropenia

Sevinc, A
Ozkan, M
Ozet, A
Dane, F
Oksuzoglu, B
Isikdogan, A
Ozdemir, F
Uncu, D
Gumus, M
Evrensel, T
Yaren, A
Kara, O
Tekin, SB

January 2018

Background: We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim...

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar

Schwartzberg LS
Lal LS
Balu S
Campbell K
Brekke L
Elliott C
Korrer S

September 2018

Lee S Schwartzberg,1,2 Lincy S Lal,3 Sanjeev Balu,4 Kim Campbell,4 Lee Brekke,3 Caitlin Elliott,3 St...

A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients

Roberto Hegg
André Mattar
João Nunes de Matos-Neto
José Luiz Pedrini
Sabina Bandeira Aleixo
Roberto Odebrecht Rocha
Renato Peixoto Cramer-Junior
Sylvie van-Eyll-Rocha

OBJECTIVES: To compare the efficacy and safety of two filgrastim formulations for controlling chemot...

Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy

Kalpna Desai
Priya Misra
Sanyukta Kher
Nirmesh Shah

September 2018

Abstract Background Chemotherapy-induced neutropenia is a common result of myelosuppressive chemothe...

The Real-World Experience of the Biosimilar (Grastofil®) to the Reference Biologic (Neupogen®) in Breast Cancer and Lymphoma: A Canadian Single-Centre Retrospective Study

Wong, Gina
Wang, Katie
Pasetka, Mark
Zhang, Liying
Lou, Julia
Majeed, Habeeb
Flores, Jerome
Lam, Emily
DeAngelis, Carlo

February 2022

Febrile neutropenia (FN) is a common side effect of cytotoxic chemotherapy that may result in poor t...

Shahab, Shania
S, Ahmad

January 2024

7-15Biologics have no true generics due to their complex nature but biosimilars offer a hopeful alte...

Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study

Shi, Yuan-Kai
Chen, Qiang
Zhu, Yun-Zhong
He, Xiao-Hui
Wang, Hua-Qing
Jiang, Ze-Fei
Chang, Jian Hua
Liu, Yun-Peng
Wang, An-Lan
Luo, De-Yun
Zhang, Yang
Ke, Xiao-Yan
Li, Wei-Lian
Zhang, Wei-Jing
Wang, Xiu-Wen
Zhang, Yi-Ping
Wang, Jian-Min
Liu, Xiao-Qing

January 2013

The purpose of this study was to compare the efficacy and safety of a single subcutaneous injection ...

A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients

Hegg, Roberto
Mattar, André
Matos-Neto, João Nunes de
Pedrini, José Luiz
Aleixo, Sabina Bandeira
Rocha, Roberto Odebrecht
Cramer-Junior, Renato Peixoto
van-Eyll-Rocha, Sylvie

October 2016

OBJECTIVES: To compare the efficacy and safety of two filgrastim formulations for controlling chemot...

Caselli, Désirée
CESARO, SIMONE
Aricò, Maurizio

January 2016

Advances in chemotherapy and surgery allows the majority of patients to survive cancer diseases. Yet...

Comparison of the effects of two different doses of Filgrastim in febrile neutropenia management in childhood malignancy: A randomized clinical trial

Mirbehbahani, N.
Bagheri, S.
Roshandel, G.
Jahazi, A.
Rashidbaghan, A.

January 2022

Background: Febrile neutropenia (FN) is most often caused due to chemotherapy. Solid or certain lymp...

ONE YEAR OF BIOSIMILAR FILGRASTIM IN ROUTINE CLINICAL PRACTICE

Maria Sofia Rosati
Giulia Baciarello
Maria Luisa Basile
Serena Zancla
Ersilia Ranieri

January 2012

Objectives: The use of biosimilar filgrastim has been debated for the limited experience at the time...

Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia.

Abstract

Extracted data

Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia.

Abstract

Extracted data

Related items

Related items